Insights
Senate Democrats Reintroduce Comprehensive Cannabis Descheduling Bill, Renewing Push for Federal Reform
WASHINGTON, D.C. - The push for comprehensive federal Cannabis reform has returned to the U.S. Senate with the reintroduction of the Cannabis Administration and Opportunity Act (CAOA), a sweeping piece of legislation that would remove Cannabis from the federal Controlled Substances Act and establish a national framework for regulating the industry. Introduced by Cory Booker, ...
California’s Cannabis Promise Remains Unfulfilled: Why Racial Disparities in Cannabis Arrests Continue to Shame the Golden State
SACRAMENTO- Nearly a decade after California voters approved adult-use Cannabis, the state has become one of the world's largest legal Cannabis markets. Billions of dollars have flowed through licensed businesses, thousands of jobs have been created, and Cannabis has become increasingly accepted by mainstream society. Yet beneath these successes lies an uncomfortable reality. For many ...
FDA Finalizes Psychedelic Drug Guidance and Schedules September Public Hearing
WASHINGTON, D.C., The US FDA has established clearer expectations for psychedelic clinical trials while inviting public input on how the therapies could eventually be delivered in supervised healthcare settings. The U.S. Food and Drug Administration has finalized its long-awaited guidance for companies and researchers developing psychedelic medicines, marking an important step toward bringing the emerging ...
Lazear Advises Medical Cannabis Company Organic Remedies on ESOP Transaction
COLUMBUS, Ohio, July 6, 2026 – Organic Remedies, one of Pennsylvania's leading medical cannabis companies, has completed its transition to 100% employee ownership through an Employee Stock Ownership Plan (ESOP), marking another milestone in the growing adoption of ESOPs as an ownership transition strategy for the cannabis industry. Lazear Capital Partners (Lazear) served as the ...
California’s Legal Cannabis Market Holds Steady at Midyear
LOS ANGELES – California's licensed retailers generated $323.1 million in Cannabis sales in June, pushing the state's first-half total to nearly $1.95 billion. The June figure landed almost exactly in line with the roughly $322 million sold in June 2025, marking one of the cleaner year-over-year comparisons California's licensed sector has produced in several years. ...
Glass House Brands Applies for NYSE Uplisting
LONG BEACH – Glass House Brands Inc., a vertically integrated Cannabis company concentrated in California, announced it has applied to list its subordinate voting shares on the New York Stock Exchange. The filing is among the most concrete steps any U.S. multistate Cannabis operator has taken toward a place on a major American exchange. Glass ...
Trulieve Approved to Uplist to NYSE in Historic Milestone for U.S. Cannabis Industry
TALLAHASSEE, Fla. — June 5, 2026 — In a landmark moment for the U.S. Cannabis industry, Trulieve Cannabis Corp. announced today that it has received approval to list its subordinate voting shares on the New York Stock Exchange (NYSE), becoming one of the first major U.S. Cannabis operators to secure a listing on a premier ...
Abstrax Earns Spot on Fast Company’s Most Innovative Companies List
IRVINE – Abstrax, the botanical flavor science company that built its foundation on essential oils and Cannabis terpene research, has been named to Fast Company's 2026 list of the World's Most Innovative Companies, placing fifth in the Manufacturing category among 720 honorees across 59 sectors and regions. Founded in California in 2017, Abstrax began with ...
Oregon Completes First Full Year of Psilocybin Services Data Collection
SALEM – Oregon Psilocybin Services (OPS) has wrapped up its 2025 quarterly reporting, giving the public its clearest view yet of how the state's regulated program performed over a full calendar year. Psychedelic Alpha released its summary of the Q4 data, drawing from official state dashboards to highlight trends in client numbers, session formats, safety ...
GCNC-Whitney Economics Report Provides Updated Insights on EU & UK Cannabis Markets
LONDON – The Global Cannabis Network Collective (GCNC) and Whitney Economics released What You Need to Know: EU & UK Cannabis Market Update this week at the Cannabis Europa 2026 conference in London, presenting a detailed assessment of the forces currently reshaping Cannabis across the European Union and the United Kingdom. The report combines quantitative ...
Cannabis 3.0: Why the Next Phase of the Industry Will Be Built on Platforms, Not Products
NEW YORK- The Cannabis industry is entering a new phase of development. The first phase of the legal Cannabis market was defined by access. Cannabis 1.0 was about legalization, licensing, compliance, and the basic right of consumers and patients to purchase regulated products. The central question was whether legal Cannabis could exist at all. Operators, ...
What’s in a Jar? For Cannabis Concentrate Brands, Quite a Lot
LOS ANGELES – The packaging debate in Cannabis manufacturing rarely makes headlines. But the choice between glass and plastic for concentrate products is one that shapes what a brand becomes and what it can prove. The global Cannabis concentrate market, valued at roughly $1.6 billion in 2025, is projected to reach $9 billion by 2036 ...
UK Medical Cannabis H1 2025: The Market Still Running on Trust
LONDON – You won't find the echoes of this revolution in the National Health Service (NHS) waiting lists or General Practitioner (GP) surgeries. It lives instead in a constellation of private clinics spread across the country, in carefully labelled jars of flower, in the inboxes of tens of thousands of patients who, until recently, had ...
Virginia Cannabis Licenses Delayed Again After Spanberger Veto
RICHMOND-Virginia’s long-delayed adult-use Cannabis market has suffered another major setback after Governor Abigail Spanberger vetoed legislation that would have created a regulated retail sales framework for the Commonwealth. The veto means Virginia will remain in the unusual position of allowing adult possession and home cultivation while continuing to block a legal adult-use retail market. For ...
Research and Markets Report Sets a $28B Target on Cannabis Tech
DUBLIN – The Cannabis industry has transformed from plant cultivation to infrastructure development. Today, institutional-grade technologies reshape the way the global supply chain works, and the numbers behind this evolution are capturing the attention of sectors far beyond Cannabis. A new report from Research and Markets places the global Cannabis technology sector on track to ...
Europe Medical Cannabis to Reach $13 Billion by 2034, IMARC Group Reports
NEW YORK – A fresh industry report highlights substantial potential in Europe's regulated medical Cannabis market as more countries refine access rules and patient numbers climb. The analysis from IMARC Group points to steady expansion driven by policy shifts and clinical demand, offering a snapshot of where the sector stands today. Germany remains the clear ...
BREAKING: Colorado Passes Landmark Ibogaine Research Bill, Expanding the State’s Natural Medicine Framework
DENVER- Colorado has taken another major step in the evolution of regulated psychedelic medicine. The Colorado legislature has passed House Bill 26-1325, a landmark measure that establishes an ibogaine research pilot program within the state’s Behavioral Health Administration. The bill authorizes up to five research sites to study the safety and effectiveness of ibogaine for ...
The DEA Window: The Real Fight Is Over Who Qualifies as Medical Cannabis
WASHINGTON, D.C. - The real significance of the DEA window is not that the Cannabis industry needs another explanation of legalization. Operators, investors, attorneys, and regulators already understand the limits of federal reform. The more important issue is whether state medical Cannabis licenses, medical designations, and documented medical operations will be enough to qualify under ...
Study: Older Americans Are Turning to Cannabis as an Alternative to Pharmaceuticals
NEW YORK - Older Americans are increasingly looking at Cannabis not as a lifestyle product, but as a practical alternative to traditional pharmaceuticals. A new study highlighted by NORML points to a growing trend among adults aged 60 and older: many are turning to Cannabis products because they are dissatisfied with conventional medications, concerned about ...
Cannabis 3.0: From Getting High to Getting Clinical
NEW YORK-Cannabis is entering a new phase, and this one is about much more than consumption. For decades, Cannabis was trapped in prohibition and treated mainly as a legal problem. Then came commercialization, when Cannabis became a consumer product defined by branding, potency, strain names, and the promise of a certain experience. Both phases mattered, ...
Israeli Cannabis Breakthrough Opens New Hope for Fatty Liver Disease
NEW YORK- A new study out of Israel has put Cannabis back into one of the most important conversations in modern medicine: metabolic disease. Researchers at the Hebrew University of Jerusalem have reported that two non-intoxicating Cannabis compounds, CBD and CBG, significantly reduced liver fat and improved metabolic health in experimental models of fatty liver ...
Why the Endocannabinoid System Is the Future of Cannabis Medicine
NEW YORK- Cannabis medicine is entering a more serious phase. For years, the conversation has focused on pain, sleep, anxiety, appetite, and symptom relief. Those remain important, but they may only be the beginning. The deeper opportunity is understanding how Cannabis interacts with one of the body’s most important regulatory networks: the endocannabinoid system. The ...
Cannabis, Inflammation, and the Next Frontier in Root-Cause Medicine
NEW YORK- Cannabis medicine is moving beyond pain, sleep, and anxiety. One of the most important next frontiers may be inflammation, because the endocannabinoid system plays a direct role in how the body regulates immune response, inflammatory signaling, pain, metabolism, and recovery. That matters because chronic inflammation is not just a symptom of disease. It ...
Why Metabolic Dysfunction May Be the Next Frontier for Cannabinoid Medicine
NEW YORK- Metabolism is the system that determines how the body produces, distributes, and uses energy, and it sits at the center of modern chronic disease. While it is often reduced to a discussion of calories or weight, metabolism is fundamentally a cellular process governed by hormonal signaling, mitochondrial function, and nutrient utilization. When it ...
LeafLink Releases 2026 Wholesale Cannabis Pricing Guide
NEW YORK – LeafLink, a unified B2B marketplace and technology platform built specifically for the Cannabis industry, published its annual 2026 Wholesale Cannabis Pricing Guide, delivering one of the most comprehensive data snapshots the legal Cannabis trade has produced to date. The report draws on billions of dollars in actual transactions and covers more than ...
